Davidsenbundgaard2629
In this research, a redundant cable-driven robust rehabilitation robot has been proposed for helping and automating the proper function of the patient's lower and upper limbs in the presence of uncertainties, disturbances, noise, and time delay using a new control algorithm to derive the best tracking with the least deviations. A new joint limit avoidance path-planning method is exerted while maintaining the bounds of upper and lower angles. Also, a new robust motion controller, namely computed-torque-like controller with a variable-structure compensator was applied to the system and compared with computed-torque controller outputs. Thus, showing the efficiency of the mentioned control algorithm in the presence of uncertainties, disturbances, noise, and time delay and its superior performance and robustness in spatial motions are the goals of this paper as well as taking advantage of a new path-planning approach. Firstly, the kinematic formulation of the cables is obtained. Then, a joint limit avoidance theorhe presence of the time delay respectively. Similar results were obtained for the upper limb with 21 percent improvement in control inputs and 21.1 percent improvement in tracking performance respectively.For multiple missile simultaneously intercepting a maneuvering target, under the directed communication topologies between missiles, this paper designs a fixed-time cooperative guidance law based on three-dimensional guidance system. Furthermore, the radial velocity measurements are not required for the designed method. First, we construct the cooperative guidance model by using the three-dimensional missile-target intercepting geometry. Then, based on the fixed-time differentiator and the bi-limit homogeneity theory, a consensus protocol is designed in line-of-sight (LOS) direction, which can ensure missile's impact time achieve fixed-time consensus. Next, in normal direction of LOS, two continuous adaptive fixed-time guidance laws are designed to guarantee LOS angular rates achieve fixed-time convergence. Finally, the excellent performance of the designed method is validated by simulation results.Human leukocyte antigen (HLA) genes with extreme diversity can make a contribution for individual variations to the immune response against SARS-COV-2 infection. This study aimed to explore the distributions of HLA class II alleles frequencies and their relations with disease severity in a group of Iranian COVID-19 patients. This prospective and case-control study was conducted on 144 COVID-19 patients including 46 cases with moderate form, 54 cases with severe and 44 cases with critical disease. HLA-DRB1 and -DQB1 allele families were determined by PCR-SSP method and compared between three groups of the patients and in comparison to 153 ethnic-matched healthy controls. The patients group showed lower frequencies of HLA-DRB1*15 (OR = 0.57, P = 0.06), DRB1*15 ~ DQB1*05 haplotype (P = 0.04) and DRB1*15/DRB1*04 genotype (P = 0.04) in compare with healthy controls. Moderate COVID-19 patients had higher frequencies of HLA-DRB1*04 (P = 0.03), HLA-DRB1*10 (P = 0.05) and DRB1*04/DRB1*11 genotype (P = 0.01). Also, a higher significantly frequency of HLA-DRB1*03 allele group was observed in the critical patients versus controls (P = 0.01). read more Multiple logistic regression analysis revealed that the presence of DRB1*04 allele group was negatively associated with development of severe and critical disease (OR 0.289, P = 0.005). Our results indicate a possible contribution of some HLA class II alleles in disease severity and clinical features of COVID-19 disease.Th9 is a subset of CD4+ T cells that mainly secrete IL-9. Th9/IL-9 participates in immune response during Staphylococcus aureus and methicillin-resistant Staphylococcus aureus pneumonia (MRSA) infection. Here, we collected bronchoalveolar lavage fluid (BALF) from 30 children with MRSA pneumonia (MRSA group) and 10 children with bronchial foreign bodies (Control group). RT-PCR, ELISA and flow cytometry were used to detect the expression of miR-155 and IL-9 in BALF and the number of Th9 cells. CD4+ T cells isolated from BALF of MRSA and Control group were transfected with miR-155 mimic or inhibitor, and then induced Th9 cell differentiation. The results showed that the expression of miR-155 and IL-9 were significantly increased in BALF and Th9 cell of MRSA group, as well as the number of Th9 cells. miR-155 mimic upregulated IL-9 mRNA expression, IL-9 secretion and increased number of Th9 cells. On the contrary, miR-155 inhibitor inhibited IL-9 mRNA expression, IL-9 secretion and decreased number of Th9 cells. The dual luciferase assays demonstrated miR-155 can target binding to SIRT1 3'UTR. Moreover, overexpression of SIRT1 could reverse the effect of miR-155 mimic on IL-9 expression level, Th9 cell number and transcription factors PU.1 and IRF4 expression. In conclusion, miR-155 regulates Th9 differentiation in children with MRSA by targeting SIRT1.Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in development, including compounds targeting G-protein coupled receptors, glutamate, ion channels, and neuromodulatory devices. Emergence of these new interventions could complement our current treatment armamentarium for migraine management.
To investigate whether dry eye disease (DED) is a risk factor for COVID-19.
In this retrospective cohort study, patients who were diagnosed with DED by an ophthalmologist and whose Schirmer test was less than 5mm were identified. Patients who missed follow-up examinations, patients with malignancy, Human Immunodeficiency Virus patients and patients having undergone bone marrow transplantation were excluded. Among the DED patients, patients with positive SARS-CoV-2 PCR tests were identified on October 11, 2020. Subsequently, patients were divided into four age groups (25-49; 50-64; 65-79; and 80+). The COVID-19 prevalence per 100,000 people was determined for each age group, and risk analysis was performed by comparing this with the general population in Turkey.
In total, 10,023 DED patients were identified and included in the study. Among these, the PCR test was positive in 359 patients. The COVID-19 prevalence per 100,000 population in DED patients was calculated as 3581.7, while according to the Ministry of Health data, it was 524.